Achieve Life Sciences (ACHV) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Transition Report	false
Document Quarterly Report	true
Trading Symbol	ACHV
Entity Incorporation, State or Country Code	DE
Entity Registrant Name	Achieve Life Sciences, Inc.
Entity Central Index Key	0000949858
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	033-80623
Entity Tax Identification Number	95-4343413
Entity Address, Address Line One	1040 West Georgia Street
Entity Address, Address Line Two	Suite 1030
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6E 4H1
City Area Code	604
Local Phone Number	210-2217
Entity Common Stock, Shares Outstanding		9,710,747
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents [note 6]	$ 18,197	$ 43,022
Grant receivable [note 3]	145	153
Prepaid expenses and other assets	2,615	1,419
Total current assets	20,957	44,594
Right-of-use assets [note 9]	18	64
Other assets and restricted cash [note 6]	239	183
License agreement [note 4 and 5]	1,475	1,641
Goodwill [note 5]	1,034	1,034
Total assets	23,723	47,516
Current liabilities:
Accounts payable	412	841
Accrued liabilities other	539	348
Accrued clinical liabilities	4,552	1,352
Accrued compensation	1,390	1,940
Current portion of long-term obligations [note 9]	23	69
Total current liabilities	6,916	4,550
Convertible debt [note 7]	15,763	14,920
Long-term obligations [note 9]		4
Total liabilities	22,679	19,474
Commitments and contingencies [note 9]
Stockholders' equity:
Common stock, $0.001 par value, 150,000,000 shares authorized, 9,710,747 issued and outstanding at September 30, 2022 and 9,453,542 issued and outstanding at December 31, 2021	79	79
Additional paid-in capital	125,665	121,545
Accumulated deficit	(124,704)	(93,586)
Accumulated other comprehensive income	4	4
Total stockholders' equity	1,044	28,042
Total liabilities and stockholders' equity	23,723	47,516
Series A Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.001
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	9,710,747	9,453,542
Common stock, shares outstanding	9,710,747	9,453,542
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	9,158	9,158
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	6,256	6,256
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
EXPENSES
Research and development	$ 9,869	$ 4,591	$ 21,464	$ 19,460
General and administrative	2,770	2,102	8,474	6,519
Total operating expenses	12,639	6,693	29,938	25,979
OTHER INCOME (EXPENSE)
Interest income	73	3	81	14
Interest expense [note 7]	(481)		(1,242)
Other income (expense)	(30)	(1)	(19)	(36)
Total other (expense)	(438)	2	(1,180)	(22)
Net loss and comprehensive loss	$ (13,077)	$ (6,691)	$ (31,118)	$ (26,001)
Basic net loss per common share [note 8[d]]	$ (1.35)	$ (0.71)	$ (3.24)	$ (3.39)
Diluted net loss per common share [note 8[d]]	$ (1.35)	$ (0.71)	$ (3.24)	$ (3.39)
Weighted average shares used in computation of basic net loss per common share [note 8[d]]	9,693,788	9,452,238	9,600,947	7,670,383
Weighted average shares used in computation of diluted net loss per common share [note 8[d]]	9,693,788	9,452,238	9,600,947	7,670,383

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating Activities:
Net loss	$ (31,118)	$ (26,001)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization [note 4]	171	188
Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]]	2,492	1,693
Shares issued as settlement with trade vendor	26	41
Accrued interest on SVB convertible debt [note 7]	863
Changes in operating assets and liabilities:
Grant receivable [note 3]	8	(151)
Prepaid expenses and other assets	(1,256)	(146)
Accounts payable	(429)	483
Accrued liabilities other	191	(390)
Accrued clinical liabilities	3,200	304
Accrued compensation	(550)	(233)
Lease obligation [note 9]	(4)	(10)
Net cash used in operating activities	(26,406)	(24,222)
Financing Activities:
Proceeds from exercise of warrants	24	339
Proceeds from ATM, net of issuance costs [note 8[b]]	1,499
Financing costs relating to convertible debt with SVB [note 7]	(20)
Proceeds from employee stock purchase plan [note 8[g]]	126
Taxes paid related to net share settlement of equity awards	(47)
Net cash provided by financing activities	1,582	21,682
Effect of exchange rate changes on cash	(1)	(1)
Net decrease in cash, cash equivalents and restricted cash	(24,825)	(2,541)
Cash, cash equivalents and restricted cash at beginning of the period	43,072	35,903
Cash, cash equivalents and restricted cash at end of the period	$ 18,247	33,362
May 2021 Public Offering [Member]
Financing Activities:
Proceeds from the May 2021 public offering, net of issuance costs		$ 21,343

Consolidated Statements of Stoc

Consolidated Statements of Stockholder's Equity (Unaudited) - USD ($) $ in Thousands	Total	May 2021 Public Offering [Member]	Common stock [Member]	Common stock [Member] May 2021 Public Offering [Member]	Additional paid-in capital [Member]	Additional paid-in capital [Member] May 2021 Public Offering [Member]	Accumulated other comprehensive income (loss) [Member]	Accumulated deficit [Member]
Beginning Balance at Dec. 31, 2020	$ 37,286		$ 76		$ 97,640		$ 4	$ (60,434)
Beginning Balance, Shares at Dec. 31, 2020			6,111,735
Stock-based compensation expense	542				542
Shares issued on exercise of warrants	236				236
Shares issued on exercise of warrants, Shares			35,217
Shares issued	23				23
Shares issued, Shares			2,965
Net loss	(7,999)							(7,999)
Ending Balance at Mar. 31, 2021	30,088		$ 76		98,441		4	(68,433)
Ending Balance, Shares at Mar. 31, 2021			6,149,917
Beginning Balance at Dec. 31, 2020	$ 37,286		$ 76		97,640		4	(60,434)
Beginning Balance, Shares at Dec. 31, 2020			6,111,735
Restricted stock unit settlements, Shares	231
Net loss	$ (26,001)
Ending Balance at Sep. 30, 2021	34,700		$ 79		121,052		4	(86,435)
Ending Balance, Shares at Sep. 30, 2021			9,453,542
Beginning Balance at Mar. 31, 2021	30,088		$ 76		98,441		4	(68,433)
Beginning Balance, Shares at Mar. 31, 2021			6,149,917
Stock-based compensation expense	621				621
Shares issued on exercise of warrants	95				95
Shares issued on exercise of warrants, Shares			14,443
Shares issued	18	$ 21,343		$ 3	18	$ 21,340
Shares issued, Shares			2,149	3,285,714
Net loss	(11,311)							(11,311)
Ending Balance at Jun. 30, 2021	40,854		$ 79		120,515		4	(79,744)
Ending Balance, Shares at Jun. 30, 2021			9,452,223
Stock-based compensation expense	530				530
Shares issued on exercise of warrants	8				8
Shares issued on exercise of warrants, Shares			1,174
Restricted stock unit settlements	$ (1)				(1)
Restricted stock unit settlements, Shares	231		145
Net loss	$ (6,691)							(6,691)
Ending Balance at Sep. 30, 2021	34,700		$ 79		121,052		4	(86,435)
Ending Balance, Shares at Sep. 30, 2021			9,453,542
Beginning Balance at Dec. 31, 2021	28,042		$ 79		121,545		4	(93,586)
Beginning Balance, Shares at Dec. 31, 2021			9,453,542
Stock-based compensation expense	823				823
Shares issued on exercise of warrants	24				24
Shares issued on exercise of warrants, Shares			3,709
Shares issued from purchase agreement with Virtu	91				91
Shares issued from purchase agreement with Virtu, Shares			12,742
Shares issued	26				26
Shares issued, Shares			3,584
Net loss	(7,573)							(7,573)
Ending Balance at Mar. 31, 2022	21,433		$ 79		122,509		4	(101,159)
Ending Balance, Shares at Mar. 31, 2022			9,473,577
Beginning Balance at Dec. 31, 2021	$ 28,042		$ 79		121,545		4	(93,586)
Beginning Balance, Shares at Dec. 31, 2021			9,453,542
Restricted stock unit settlements, Shares	26,625
Net loss	$ (31,118)
Ending Balance at Sep. 30, 2022	1,044		$ 79		125,665		4	(124,704)
Ending Balance, Shares at Sep. 30, 2022			9,710,747
Beginning Balance at Mar. 31, 2022	21,433		$ 79		122,509		4	(101,159)
Beginning Balance, Shares at Mar. 31, 2022			9,473,577
Stock-based compensation expense	840				840
Shares issued from purchase agreement with Virtu	1,408				1,408
Shares issued from purchase agreement with Virtu, Shares			187,258
Restricted stock unit settlements, Shares			26,625
Restricted stock unit settlements withheld and retired to treasury	(47)				(47)
Restricted stock unit settlements withheld and retired to treasury, Shares			(5,605)
Net loss	(10,468)							(10,468)
Ending Balance at Jun. 30, 2022	13,166		$ 79		124,710		4	(111,627)
Ending Balance, Shares at Jun. 30, 2022			9,681,855
Stock-based compensation expense	$ 829				829
Restricted stock unit settlements, Shares	26,625
Shares issued under employee share purchase plan	$ 126				126
Shares issued under employee share purchase plan, Shares			28,892
Net loss	(13,077)							(13,077)
Ending Balance at Sep. 30, 2022	$ 1,044		$ 79		$ 125,665		$ 4	$ (124,704)
Ending Balance, Shares at Sep. 30, 2022			9,710,747

Nature of Business, Basis of Pr

Nature of Business, Basis of Presentation and Going Concern Uncertainty	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Nature of Business, Basis of Presentation and Going Concern Uncertainty	1. NATURE OF BUSINESS, BASIS OF PRESENTATION AND GOING CONCERN UNCERTAINTY Achieve Life Sciences, Inc. (referred to as “Achieve,” “we,” “us,” or “our”) is a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction. We were incorporated in the state of Delaware, and operate out of Vancouver, British Columbia and Seattle, Washington. The unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required to be presented for complete financial statements. The accompanying unaudited consolidated financial statements reflect all adjustments (consisting only of normal recurring items) which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. The accompanying consolidated Balance Sheet at December 31, 2021 has been derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year then ended. The unaudited consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2021 and filed with the U.S. Securities and Exchange Commission, or the SEC, on March 10, 2022. The consolidated financial statements include the accounts of Achieve and our wholly owned subsidiaries, Achieve Life Sciences Technologies Inc., Achieve Life Science, Inc., Extab Corporation, and Achieve Pharma UK Limited. All intercompany balances and transactions have been eliminated. Going Concern Uncertainty The accompanying financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. We have historically experienced recurring losses from operations and have incurred an accumulated deficit of $124.7 million through September 30, 2022. As of September 30, 2022, we had cash and cash equivalents of $18.2 million and a positive working capital balance of $14.0 million. For the nine months ended September 30, 2022, we incurred a net loss of $31.1 million and net cash used in operating activities was $26.4 million. Substantial doubt exists as to our ability to continue as a going concern. Our ability to continue as a going concern is subject to material uncertainty and dependent on our ability to obtain additional financing. There is no assurance that we will obtain financing from other sources. We have historically financed our operations through equity and debt financings. Without additional funds, we may be forced to delay, scale back or eliminate some of our research and development, or R&D, activities or other operations and potentially delay product development in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals would be adversely affected. Our current resources are insufficient to fund our planned operations for the next twelve months. We will continue to require substantial additional capital to continue our clinical development activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations from the sale of our securities, partnering arrangements or other financing transactions in order to finance the commercialization of our product candidate. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. The uncertainty with respect to our operations and the market generally due to the COVID-19 pandemic and increasing interest rates and inflation may also make it challenging to raise additional capital on favorable terms, if at all. Failure to raise capital as and when needed, on favorable terms or at all, will have a negative impact on our financial condition and our ability to develop our product candidate. We expect our R&D expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidate in clinical development. The consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern. Such adjustments could be material.

Accounting Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Accounting Policies	2. ACCOUNTING POLICIES The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures. We have discussed those estimates that we believe are critical and require the use of complex judgment in their application in our audited financial statements for the year ended December 31, 202 1 in our Annual Report on Form 10-K filed with the SEC, on March 1 0 , 202 2 . Since December 31, 2021, there have been no material changes to our critical accounting policies or the methodologies or assumptions we apply under them.

Government Grant

Government Grant	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Government Grant	3. GOVERNMENT GRANT In July 2021, we announced that we were awarded a grant from the National Institute on Drug Abuse, or NIDA, of the National Institutes of Health, or NIH, to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. This initial grant award, in the amount of $0.3 million, commenced on August 1, 2021, and was utilized to complete critical regulatory and clinical operational activities, such as protocol finalization, clinical trial site identification, drug packaging, and submission of a new Investigational New Drug Application, or IND, to the U.S. Food and Drug Administration, or FDA, for investigating cytisinicline in nicotine e-cigarette users. In June 2022, we announced the initiation of the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the efficacy and safety of 3 The full grant award of $2.8 million is expected to cover approximately half of the total ORCA-V1 clinical study costs. The Primary Investigators for the grant are our Chief Medical Officer, Dr. Cindy Jacobs, and Dr. Nancy Rigotti, Professor of Medicine at Harvard Medical School and Director, Tobacco Research and Treatment Center, Massachusetts General Hospital. For the nine months ended September 30, 2022, we incurred $0.7 million in qualifying R&D expenditures under the NIDA/NIH grant, which has been recorded as a reduction in R&D expense. As of September 30, 2022, we had $0.1 million in grant receivable related to the NIDA/NIH grant.

Intangibles

Intangibles	9 Months Ended
	Sep. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Intangibles	4. INTANGIBLES All of our intangible assets are subject to amortization and are amortized using the straight-line method over their estimated useful life. We acquired license and supply agreements in relation to cytisinicline upon the acquisition of Extab Corporation, or Extab, on May 18, 2015. The agreements were determined to have a fair value of $3.1 million with an estimated useful life of 14 years. The components of intangible assets were as follows: September 30, 2022 December 31, 2021 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying Value Amortization Value Value Amortization Value License Agreements $ 3,117 $ (1,642 ) $ 1,475 $ 3,117 $ (1,476 ) $ 1,641 For the three and nine months ended September 30 , 2022, , 2021, September 30, 2022 Year Ending December 31, 2022 56 2023 223 2024 223 Thereafter 973 Total $ 1,475 We evaluate the carrying amount of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful life or that indicate the asset may be impaired. We conducted an analysis of potential impairment indicators for long lived assets, including the license and supply agreements for the active pharmaceutical ingredient cytisinicline, and concluded that there were no indicators of impairment identified as of September 30 , 2022

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
License Agreements	5. LICENSE AGREEMENTS Sopharma License and Supply Agreements We are party to a license agreement, or the Sopharma License Agreement, and a supply agreement, or the Sopharma Supply Agreement, with Sopharma, AD, or Sopharma. Pursuant to the Sopharma License Agreement, we were granted access to all available manufacturing, efficacy and safety data related to cytisinicline, as well as a granted patent in several European countries related to new oral dosage forms of cytisinicline providing enhanced stability. Additional rights granted under the Sopharma License Agreement include the exclusive use of, and the right to sublicense, certain cytisinicline trademarks in all territories described in the Sopharma License Agreement. Under the Sopharma License Agreement, we agreed to pay a nonrefundable license fee. In addition, we agreed to make certain royalty payments equal to a mid-single digit percentage of all net sales of cytisinicline products in our territory during the term of the Sopharma License Agreement, including those sold by a third party pursuant to any sublicense which may be granted by us. To date, any amounts paid to Sopharma pursuant to the Sopharma License Agreement have been immaterial. University of Bristol License Agreement In July 2016, we entered into a license agreement with the University of Bristol, or the University of Bristol License Agreement. Under the University of Bristol License Agreement, we received exclusive and nonexclusive licenses from the University of Bristol to certain patent and technology rights resulting from research activities into cytisinicline and its derivatives, including a number of patent applications related to novel approaches to cytisinicline binding at the nicotinic receptor level. In consideration of rights granted by the University of Bristol, we paid a nominal license fee and agreed to pay amounts of up to $3.2 million, in the aggregate, tied to a financing milestone and to specific clinical development and commercialization milestones resulting from activities covered by the University of Bristol License Agreement. Additionally, if we successfully commercialize any product candidates subject to the University of Bristol License Agreement, we are responsible for royalty payments in the low-single digits and payments up to a percentage in the mid-teens of any sublicense income, subject to specified exceptions, based upon net sales of such licensed products. On January 22, 2018, we and the University of Bristol entered into an amendment to the University of Bristol License Agreement. Pursuant to the amended University of Bristol License Agreement, we received exclusive rights for all human medicinal uses of cytisinicline across all therapeutic categories from the University of Bristol from research activities into cytisinicline and its derivatives. In consideration of rights granted by the amended University of Bristol License Agreement, we agreed to pay an initial amount of $37,500 upon the execution of the amended University of Bristol License Agreement, and additional amounts of up to $1.7 million, in the aggregate, tied to a financing milestone and to specific clinical development and commercialization milestones resulting from activities covered by the amended University of Bristol License Agreement, in addition to amounts under the original University of Bristol License Agreement of up to $3.2 million in the aggregate, tied to specific financing, development and commercialization milestones. Additionally, if we successfully commercialize any product candidate subject to the amended University of Bristol License Agreement or to the original University of Bristol License Agreement, we will be responsible, as provided in the original University of Bristol License Agreement, for royalty payments in the low-single digits and payments up to a percentage in the mid-teens of any sublicense income, subject to specified exceptions, based upon net sales of such licensed products. Up to September 30, 2022

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. FAIR VALUE MEASUREMENTS Assets and liabilities recorded at fair value in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. For certain of our financial instruments including amounts receivable and accounts payable the carrying values approximate fair value due to their short-term nature. ASC 820 “Fair Value Measurements and Disclosures” specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. In accordance with ASC 820, these inputs are summarized in the three broad levels listed below: • Level 1 – Quoted prices in active markets for identical securities. • Level 2 – Other significant inputs that are observable through corroboration with market data (including quoted prices in active markets for similar securities). • Level 3 – Significant unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability. As quoted prices in active markets are not readily available for certain financial instruments, we obtain estimates for the fair value of financial instruments through third-party pricing service providers. In determining the appropriate levels, we performed a detailed analysis of the assets and liabilities that are subject to ASC 820. We invest our excess cash in accordance with investment guidelines that limit the credit exposure to any one financial institution other than securities issued by the U.S. Government. These securities are not collateralized and mature within one year. A description of the valuation techniques applied to our financial instruments measured at fair value on a recurring basis follows. Financial Instruments Money Market Securities Money market securities are classified within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets for identical securities. The following table presents information about our assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): September 30, 2022 Level 1 Level 2 Level 3 Total Assets Money market securities (cash equivalents) 15,456 — — 15,456 Restricted cash 50 — — 50 Total assets $ 15,506 $ — $ — $ 15,506 Cash equivalents consist of the following (in thousands): Gross Gross Amortized Unrealized Unrealized Estimated September 30, 2022 Cost Gains Losses Fair Value Money market securities $ 15,456 $ — $ — $ 15,456 Total cash equivalents $ 15,456 $ — $ — $ 15,456 Money market securities (restricted cash) 50 — — 50 Total restricted cash $ 50 $ — $ — $ 50 We only invest in A (or equivalent) rated securities. All securities included in cash and cash equivalents had maturities of 90 days or less at the time of purchase. Fair Value of Long-Term Debt December 2021 Convertible Debt The principal amount, carrying value and related estimated fair value of our convertible debt reported in the consolidated balance sheets as of September 30, 2022 and December 31, 2021 was as follows (in thousands). The aggregate fair value of the principal amount of the convertible debt is a Level 2 fair value measurement. September 30, 2022 December 31, 2021 Principal Carrying Fair Principal Carrying Fair Amount Value Value Amount Value Value December 2021 Convertible Debt $ 15,000 $ 15,763 $ 16,548 $ 15,000 $ 14,920 $ 15,204

Convertible Debt

Convertible Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Debt	7. CONVERTIBLE DEBT On December 22, 2021, we entered into a $25.0 million contingent convertible debt agreement, or Original Debt Agreement, with Silicon Valley Bank, or SVB, and SVB Innovation Credit Fund VIII, L.P., or, together with SVB, the Lenders. As part of the Original Debt Agreement, the Lenders funded $15.0 million in the form of convertible indebtedness, or Convertible Debt, at closing. On April 26, 2022, we entered into (i) a loan and security agreement, or Loan Agreement, with SVB for the remaining $10.0 million remaining in the Original Debt Agreement, pursuant to which SVB provided a commitment to extend term loans having an aggregate original principal amount of up to $10.0 million, or Term Loans, and (ii) a first amendment to the Original Debt Agreement, or the Amendment, and as amended by the Amendment, the Debt Agreement. Under the terms of the Debt Agreement, the Convertible Debt matures on December 22, 2023 and may be extended to December 22, 2024 upon our written request and SVB’s approval on or prior to December 22, 2023. The Convertible Debt will accrue interest at the aggregate of (a) a floating rate per annum equal to the greater of (i) 2.25% and (ii) the prime rate minus 1.0%, which interest is payable in cash monthly in arrears, and (b) 7.0% per annum, which interest shall compound monthly. Subject to certain terms and conditions, the Lenders may convert all or any part of the outstanding Convertible Debt and accrued and unpaid interest at any time prior to maturity into shares of our common stock at a conversion price equal to $9.34 per share, subject to customary anti-dilution adjustments. Additionally, all outstanding Convertible Debt, including accrued and unpaid interest, will mandatorily convert into shares of our common stock, at the conversion price, on such date, if any, when the closing price per share of our common stock has been equal to or greater than $24.00 for thirty consecutive trading days prior to such date). We have the right, or Call Right, at any time to repay and retire all (but not less than all) of the outstanding Convertible Debt and accrued and unpaid interest, if any, prior to its conversion by payment of a premium determined based on the date of such repayment equal to: i. 125% of the principal amount of the Convertible Debt including accrued paid-in-kind interest, or PIK, if the Call Right is exercised on or before the 18-month anniversary of the date of the Debt Agreement; and ii. 150% of the principal amount of the Convertible Debt including accrued PIK, if the Call Right is exercised after the 18-month anniversary of the date of the Debt Agreement, in either case together with all accrued and unpaid interest on the principal balance of the Convertible Debt. If the Call Right is exercised by us, the Lenders will retain certain lookback rights in the event we enter into an agreement to be acquired in the twelve months following the exercise of the Call Right. We agreed to grant the Lenders a security interest in virtually all of our assets, including our patents and other intellectual property as security for our obligations under the Debt Agreement. Subject to the terms and conditions of the Loan Agreement, we may borrow term loans under the Loan Agreement until April 30, 2023. Amounts borrowed under the Loan Agreement will incur interest at a floating rate equal to the greater of 3.50% and the Wall Street Journal, or WSJ, prime rate, and will be subject to interest only payments through April 30, 2024. Commencing on May 1, 2024, the outstanding loans under the Loan Agreement will be repaid in 24 consecutive equal monthly installments of principal plus accrued and unpaid interest. The Term Loans mature on April 1, 2026. Upon the earliest to occur of the maturity date, repayment of the Term Loans in full, acceleration of the loans or termination of the Loan Agreement, we will be required to pay a final payment equal to the aggregate principal amount of the Term Loan advances extended by SVB multiplied by 6.0%. Our obligations under the Loan Agreement are secured by substantially all of our assets, other than our intellectual property. Upon and after borrowing under the Loan Agreement, we must comply with certain financial covenants as set forth in the Loan Agreement and the Amendment, including a minimum liquidity ratio of at least 1.25 to 1.00, or at our election after receiving at least $30 million in net cash proceeds from the issuance and sale of equity securities, a minimum market capitalization of at least $250 million. The Loan Agreement also contains customary affirmative and restrictive covenants, including covenants regarding the incurrence of additional indebtedness or liens, investments, transactions with affiliates, delivery of financial statements, payment of taxes, maintenance of insurance, dispositions of property, mergers or acquisitions, among other customary covenants. We are also restricted from paying dividends or making other distributions or payments on its capital stock, subject to limited exceptions. The Loan Agreement includes customary representations and warranties, events of default and termination provisions. In addition to the financial covenants described above, the Amendment makes certain other changes to the Original Debt Agreement related to our entry into the Loan Agreement. As of September 30, 2022 no amounts had been drawn on the Term Loans. Under ASU 2020-06, the embedded conversion feature was not required to be bifurcated and recognized separately, as a result the convertible debt including the conversion feature has been recognized as a single unit of debt. The debt issuance costs have been recognized against the single unit of debt and will be amortized into interest expense over the term of the loan. As of September 30, 2022, the Convertible Debt balance was comprised of the following: Nine Months Ended Year Ended September 30, December 31, 2022 2021 Convertible Debt Information Principal $ 15,000 $ 15,000 Transaction Costs (84 ) (109 ) Accrued paid-in-kind interest 847 29 15,763 14,920

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Common Stock	8. COMMON STOCK [a] Authorized 150,000,000 authorized common shares, par value of $0.001, and 5,000,000 preferred shares, par value of $0.001. [b] Issued and outstanding shares May 2021 Public Offering On May 27, 2021, we completed an underwritten public offering of our securities, pursuant to which we sold an aggregate of 3,285,714 shares of our common stock, including 428,571 shares subject to the underwriter’s option to purchase additional shares, or the May Shares. The May Shares were sold at the public offering price of $7.00 per share. The underwritten public offering raised total gross proceeds of approximately $23.0 million and after deducting approximately $1.7 million in underwriting discounts and commissions and offering expenses, we received net proceeds of approximately $21.3 million. The underwriting discounts and commissions and offering expenses have been charged against the gross proceeds. At-the-Market Sales Agreement On December 21, 2021, we entered into an At-the-Market Offering Sales Agreement, or ATM, with Virtu Americas, LLC, as sales agent, pursuant to which we may sell shares of common stock with an aggregate offering price of up to $25 million. During the nine months ended September 30, 2022, we offered and sold 200,000 shares of our common stock pursuant to the ATM. These aggregate sales resulted in gross proceeds to us of approximately $1.5 million. Since entry into the ATM, from December 21, 2021 through September 30, 2022, we offered and sold an aggregate of 200,000 shares of our common stock. These aggregate sales resulted in gross proceeds to us of approximately $1.5 million. As of September 30, 2022, shares of our common stock having an aggregate value of approximately $23.5 million remained available for sale under the ATM. Equity Award Issuances and Settlements During the three and nine months ended September 30, 2022, we did not issue any shares of common stock to satisfy stock option exercises and we issued 26,625 common stock to satisfy restricted stock unit settlements. During the three and nine months ended September 30, 2021, we did not issue any shares of common stock to satisfy stock option exercises and issued 231 shares of common stock to satisfy restricted stock unit settlements. [c] Stock options 2018 Equity Incentive Plan As of September 30, 2022, we had reserved, pursuant to the 2018 Equity Incentive Plan, or the 2018 Plan, 967,152 shares of common stock for issuance upon exercise of stock options and settlement of restricted stock units by employees, directors, officers and consultants of ours, of which 714,155 were reserved for options currently outstanding, 252,875 for restricted stock units currently outstanding, and 122 were available for future equity grants. Under the 2018 Plan, we may grant options to purchase common shares or restricted stock units to our employees, directors, officers and consultants. The exercise price of the options is determined by our board of directors, or Board, but will be at least equal to the fair value of the shares of common stock at the grant date. The options vest in accordance with terms as determined by our Board, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our Board. The expiry date for each option is set by our Board with a maximum expiry date of ten years from the date of grant. In addition, the 2018 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees. New Employee Inducement Grants We grant stock options as a material inducement to new employees for entering into employment agreements with us in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options approved under the inducement grants are issued pursuant to a stock option agreement on terms substantially similar to those described in our 2018 Plan. The exercise price of the options is determined by our board of directors but will be at least equal to the fair value of the common shares at the grant date. The options vest in accordance with terms as determined by our board of directors. The expiry date for each option is set by our board of directors with a maximum expiry date of ten years from the date of grant. For the nine months ended September 30, 2022, we granted 50,000 inducement stock options to new employees. As of September 30, 2022, 95,000 stock options granted as new employee inducement grants were outstanding. 2017 Equity Incentive Plan As of September 30 , 2022 Under the 2017 Plan, we granted options to purchase shares of common stock or restricted stock units to our employees, directors, officers and consultants. The exercise price of the options was determined by our board of directors but was at least equal to the fair value of the shares of common stock at the grant date. The options vest in accordance with terms as determined by our Board, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our Board. The expiry date for each option was set by our Board with a maximum expiry date of ten years from the date of grant. In addition, the 2017 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees. 2010 Performance Incentive Plan As of September 30 , 2022 Under the 2010 Plan we granted options to purchase shares of common stock and restricted stock units to our employees, directors, officers and consultants. The exercise price of the options was determined by our board of directors and was at least equal to the fair value of the shares of common stock at the grant date. The options vest in accordance with terms as determined by our Board, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our Board. The expiry date for each option is set by our Board with a maximum expiry date of ten years from the date of grant. In addition, the 2010 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees. Stock Option Summary We grant stock options that vest over time in accordance with terms as determined by our Board, which are typically four years for employee and consultant grants and one to three years for Board option grants. We also grant stock option awards that vest in conjunction with certain performance conditions to executive officers, employees and consultants. At each reporting date, we are required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance condition. The expiry date for each option is set by our Board, which is typically seven to ten years. The exercise price of the options is determined by our Board. Stock option transactions and the number of stock options outstanding are summarized below: Number of Weighted Optioned Average Common Exercise Shares Price Balance, December 31, 2021 522,090 $ 26.11 Granted 300,450 7.83 Expired (25 ) 28,522.56 Balance, September 30, 2022 822,515 $ 18.57 The fair value of each stock award for employees and directors is estimated on the grant date and for consultants at each reporting period, using the Black-Scholes option-pricing model based on the weighted-average assumptions noted in the following table: Nine Months Ended September 30, 2022 2021 Risk-free interest rates 1.65 % 0.64 % Expected dividend yield 0 % 0 % Expected life 5.80 5.99 Expected volatility 122.80 % 109.61 % The expected life was calculated based on the simplified method as permitted by the SEC’s Staff Accounting Bulletin 110, Share-Based Payment The results for the periods set forth below included share-based compensation expense for stock options, restricted stock units and employee share purchase plan compensation expenses in the following expense categories of the consolidated statements of loss (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Research and development $ 288 $ 162 $ 852 $ 526 General and administrative $ 541 368 1,640 1,167 Total stock-based compensation $ 829 $ 530 $ 2,492 $ 1,693 As of September 30 , 2022, , 2022 [d] Loss Per Share For the nine months ended September 30, 2022 [ e ] Restricted Stock Unit Awards We grant restricted stock unit awards that generally vest and are expensed over a four-year , 2022 The following table summarizes our restricted stock unit award activity during the nine months ended September 30, 2022 Weighted Number Average of Grant Date Shares Fair Value Balance, December 31, 2021 53,250 $ 13.09 Granted 226,250 8.26 Released (26,625 ) 13.09 Balance, September 30, 2022 252,875 $ 8.77 As of September 30, 2022 [ f ] Non-employee options and restricted stock units We recognize non-employee stock-based compensation expense over the period of expected service by the non-employee. As the service is performed, we are required to update our valuation assumptions, re-measure unvested options and restricted stock units and record the stock-based compensation using the valuation as of the vesting date. This differs from the accounting for employee awards where the fair value is determined at the grant date and is not subsequently adjusted. This re-measurement may result in higher or lower stock-based compensation expense in the Consolidated Statements of Loss and Comprehensive Loss. As such, changes in the market price of our stock could materially change the value of an option or restricted stock unit and the resulting stock-based compensation expense. [ g ] Employee Share Purchase Plan Our board of directors and stockholders approved the 2017 Employee Stock Purchase Plan , or [ h ] Common Stock Warrants The following is a summary of outstanding warrants to purchase common stock as at September 30 , 2022 Total Outstanding Exercise and price per Exercisable Share Expiration Date (1) Warrants issued in September 2017 financing 411 $ 699.200 March 2023 (2) Warrants issued in June 2018 financing 114,100 $ 80.000 June 2023 (3) Warrants issued in October 2018 financing 31,215 $ 62.890 October 2023 (4) Warrants issued in May 2019 financing 60,000 $ 90.000 May 2025 (5) Warrants issued in December 2019 financing 609,258 $ 6.600 December 2024 (6) Warrants issued in April 2020 financing 182,461 $ 7.240 April 2025 (7) Warrants issued in April 2020 financing 24,375 $ 7.320 April 2025 (8) Warrants issued in April 2020 financing 25,270 $ 7.590 April 2025 (9) Pre-Funded warrants issued in August 2020 financing 142,857 $ 0.001 * (10) Warrants issued in December 2020 financing 50,000 $ 8.750 December 2025 *The pre-funded warrants do not have an expiration date. For the nine months ended September 30, 2022, warrants to purchase 3,709 shares, issued in the December 2019 financing, were exercised at a per share price of $6.60, for proceeds of $24,480. For the nine months ended September 30, 2021, warrants to purchase 47,084 shares, issued in the December 2019 financing, were exercised at a per share price of $6.60, for proceeds of $0.3 million and warrants to purchase 3,750 shares issued in the April 2020 financing were exercised for a per share price of $7.32, for proceeds of $27,450. As of September 30, 2022, all of our outstanding warrants were classified as equity.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES The following table summarizes our contractual obligations as of September 30, 2022 (in thousands): Total Less than 1 year 1-3 years 3-5 years More than 5 years Vancouver office operating lease $ 21 $ 21 $ — $ — $ — Total $ 21 $ 21 $ — $ — $ — Leases We have operating leases for our corporate offices. Operating leases with a term of 12 months or longer are included in ROU assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use the incremental borrowing rate of comparable companies from a representative peer group selected based on industry and market capitalization. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Vancouver lease arrangement On November 19, 2018, we entered into a lease agreement, or the Vancouver Lease, for new office space in Vancouver, British Columbia, which commenced on February 1, 2019. Pursuant to the terms of the lease agreement, we leased approximately 2,367 square feet located at Suite 1030, The Grosvenor Building, 1040 West Georgia Street, Vancouver, B.C. The initial term of the Vancouver Lease will expire on January 31, 2023, with an option to extend the term for one further four-year security deposit of approximately $ 18,600 upon entering into the lease agreement. The security deposit was reduced by the first month’s rent and operating expenses upon commencement of the Vancouver Lease. The Vancouver Lease was classified as an operating lease. Future minimum lease payments under the Vancouver Lease are as follows (in thousands): 2022 16 2023 5 Total $ 21 Seattle lease arrangement On December 11, 2017, we entered into a lease, or the Seattle Lease, with 520 Pike Street, Inc., or Pike, pursuant to which we leased approximately 3,187 square feet located at Suite 2250 at 520 Pike Tower, Seattle, Washington, 98101, which commenced on March 1, 2018. The Seattle Lease expired on March 1, 2021 and was not renewed. Our monthly base rent for the premises started at approximately $11,685 which commenced on March 1, 2018 and increased on an annual basis up to approximately $12,397. In addition, we paid a security deposit to Pike in the amount of $37,192, that was subject to periodic reductions on the anniversary of the Seattle Lease. After the first anniversary of the Seattle Lease, we received a payment of $12,397, after the second anniversary, $12,397 from the security deposit was applied against one month of rent and on termination of the Seattle Lease, we received a payment of the $12,397 for the remaining amount in the security deposit. The Seattle Lease was classified as an operating lease. Consolidated rent expense relating to the Vancouver, British Columbia office, for the three and nine months ended September 30, 2022 was $25,000 and $91,000, respectively. Consolidated rent expense relating to the Vancouver, British Columbia and Seattle Washington offices for the three and nine months ended September 30, 2021 was $29,000 and $0.1 million, respectively. Other information related to leases was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows to operating leases $ 16 $ 15 $ 45 $ 68 Right-of-use assets obtained in exchange for lease obligations: Operating leases — — — — Weighted Average Remaining Lease Term Operating leases 0.33 years 1.33 years 0.33 years 1.33 years Weighted Average Discount Rate Operating leases 9.97 % 9.97 % 9.97 % 9.97 % Guarantees and Indemnifications We indemnify our officers, directors and certain consultants for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at its request in such capacity. The term of the indemnification period is equal to the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, we have obtained director and officer insurance that limits our exposure and may enable us to recover a portion of any future amounts paid. We believe that the fair value of these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations as of September 30, 2022. We have certain agreements with certain organizations with which we do business that contain indemnification provisions pursuant to which we typically agree to indemnify the party against certain types of third-party claims. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for, or expenses related to, indemnification issues for any period presented.

Intangibles (Tables)

Intangibles (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	The components of intangible assets were as follows: September 30, 2022 December 31, 2021 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying Value Amortization Value Value Amortization Value License Agreements $ 3,117 $ (1,642 ) $ 1,475 $ 3,117 $ (1,476 ) $ 1,641
Estimated Future Amortization Expense Related to Intangible Assets	The following table outlines the estimated future amortization expense related to intangible assets held as of September 30, 2022 Year Ending December 31, 2022 56 2023 223 2024 223 Thereafter 973 Total $ 1,475

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Assets Measured at Fair Value on Recurring Basis	The following table presents information about our assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): September 30, 2022 Level 1 Level 2 Level 3 Total Assets Money market securities (cash equivalents) 15,456 — — 15,456 Restricted cash 50 — — 50 Total assets $ 15,506 $ — $ — $ 15,506
Summary of Cash Equivalents	Cash equivalents consist of the following (in thousands): Gross Gross Amortized Unrealized Unrealized Estimated September 30, 2022 Cost Gains Losses Fair Value Money market securities $ 15,456 $ — $ — $ 15,456 Total cash equivalents $ 15,456 $ — $ — $ 15,456 Money market securities (restricted cash) 50 — — 50 Total restricted cash $ 50 $ — $ — $ 50
Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt	The aggregate fair value of the principal amount of the convertible debt is a Level 2 fair value measurement. September 30, 2022 December 31, 2021 Principal Carrying Fair Principal Carrying Fair Amount Value Value Amount Value Value December 2021 Convertible Debt $ 15,000 $ 15,763 $ 16,548 $ 15,000 $ 14,920 $ 15,204 As of September 30, 2022, the Convertible Debt balance was comprised of the following: Nine Months Ended Year Ended September 30, December 31, 2022 2021 Convertible Debt Information Principal $ 15,000 $ 15,000 Transaction Costs (84 ) (109 ) Accrued paid-in-kind interest 847 29 15,763 14,920

Convertible Debt (Tables)

Convertible Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt	The aggregate fair value of the principal amount of the convertible debt is a Level 2 fair value measurement. September 30, 2022 December 31, 2021 Principal Carrying Fair Principal Carrying Fair Amount Value Value Amount Value Value December 2021 Convertible Debt $ 15,000 $ 15,763 $ 16,548 $ 15,000 $ 14,920 $ 15,204 As of September 30, 2022, the Convertible Debt balance was comprised of the following: Nine Months Ended Year Ended September 30, December 31, 2022 2021 Convertible Debt Information Principal $ 15,000 $ 15,000 Transaction Costs (84 ) (109 ) Accrued paid-in-kind interest 847 29 15,763 14,920

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Summary of Stock Options Activity	Stock option transactions and the number of stock options outstanding are summarized below: Number of Weighted Optioned Average Common Exercise Shares Price Balance, December 31, 2021 522,090 $ 26.11 Granted 300,450 7.83 Expired (25 ) 28,522.56 Balance, September 30, 2022 822,515 $ 18.57
Summary of Fair Value of Each Stock Award for Employees and Directors	The fair value of each stock award for employees and directors is estimated on the grant date and for consultants at each reporting period, using the Black-Scholes option-pricing model based on the weighted-average assumptions noted in the following table: Nine Months Ended September 30, 2022 2021 Risk-free interest rates 1.65 % 0.64 % Expected dividend yield 0 % 0 % Expected life 5.80 5.99 Expected volatility 122.80 % 109.61 %
Summary of Share-Based Compensation Expense	The results for the periods set forth below included share-based compensation expense for stock options, restricted stock units and employee share purchase plan compensation expenses in the following expense categories of the consolidated statements of loss (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Research and development $ 288 $ 162 $ 852 $ 526 General and administrative $ 541 368 1,640 1,167 Total stock-based compensation $ 829 $ 530 $ 2,492 $ 1,693
Summary of Restricted Stock Unit Award Activity	The following table summarizes our restricted stock unit award activity during the nine months ended September 30, 2022 Weighted Number Average of Grant Date Shares Fair Value Balance, December 31, 2021 53,250 $ 13.09 Granted 226,250 8.26 Released (26,625 ) 13.09 Balance, September 30, 2022 252,875 $ 8.77
Summary of Outstanding Warrants	The following is a summary of outstanding warrants to purchase common stock as at September 30 , 2022 Total Outstanding Exercise and price per Exercisable Share Expiration Date (1) Warrants issued in September 2017 financing 411 $ 699.200 March 2023 (2) Warrants issued in June 2018 financing 114,100 $ 80.000 June 2023 (3) Warrants issued in October 2018 financing 31,215 $ 62.890 October 2023 (4) Warrants issued in May 2019 financing 60,000 $ 90.000 May 2025 (5) Warrants issued in December 2019 financing 609,258 $ 6.600 December 2024 (6) Warrants issued in April 2020 financing 182,461 $ 7.240 April 2025 (7) Warrants issued in April 2020 financing 24,375 $ 7.320 April 2025 (8) Warrants issued in April 2020 financing 25,270 $ 7.590 April 2025 (9) Pre-Funded warrants issued in August 2020 financing 142,857 $ 0.001 * (10) Warrants issued in December 2020 financing 50,000 $ 8.750 December 2025 *The pre-funded warrants do not have an expiration date.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Operating Leased Assets [Line Items]
Summary of Contractual Obligations	The following table summarizes our contractual obligations as of September 30, 2022 (in thousands): Total Less than 1 year 1-3 years 3-5 years More than 5 years Vancouver office operating lease $ 21 $ 21 $ — $ — $ — Total $ 21 $ 21 $ — $ — $ —
Summary of Other Information Related to Leases	Other information related to leases was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows to operating leases $ 16 $ 15 $ 45 $ 68 Right-of-use assets obtained in exchange for lease obligations: Operating leases — — — — Weighted Average Remaining Lease Term Operating leases 0.33 years 1.33 years 0.33 years 1.33 years Weighted Average Discount Rate Operating leases 9.97 % 9.97 % 9.97 % 9.97 %
Vancouver Office Operating Lease [Member]
Operating Leased Assets [Line Items]
Summary of Future Minimum Annual Lease Payments	Future minimum lease payments under the Vancouver Lease are as follows (in thousands): 2022 16 2023 5 Total $ 21

Nature of Business, Basis of _2

Nature of Business, Basis of Presentation and Going Concern Uncertainty - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accounting Policies [Abstract]
Accumulated deficit	$ (124,704)						$ (124,704)		$ (93,586)
Net loss	(13,077)	$ (10,468)	$ (7,573)	$ (6,691)	$ (11,311)	$ (7,999)	(31,118)	$ (26,001)
Cash and cash equivalents	18,197						18,197		$ 43,022
Working capital	$ 14,000						14,000
Net cash used in operating activities							$ 26,406	$ 24,222

Government Grant - Additional I

Government Grant - Additional Information (Details) - USD ($) $ in Thousands		9 Months Ended
	Aug. 01, 2021	Sep. 30, 2022	Dec. 31, 2021
Government Grant [Line Items]
Grant receivable		$ 145	$ 153
NIDA
Government Grant [Line Items]
Grant awarded	$ 300	2,500
ORCA-V1 Clinical Study Costs
Government Grant [Line Items]
Grant awarded		2,800
NIDA/NIH
Government Grant [Line Items]
Reduction in R&D expense		700
Grant receivable		$ 100

Intangibles - Additional Inform

Intangibles - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	May 18, 2015	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible assets, Fair Value	$ 3,100,000
Intangible assets, Useful life	14 years
License agreement amortization expense		$ 100,000	$ 100,000	$ 200,000	$ 200,000
Impairment of intangible assets				$ 0

Intangibles - Components of Int

Intangibles - Components of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Intangible assets, Net Carrying Value	$ 1,475	$ 1,641
License Agreements [Member]
Finite Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Value	3,117	3,117
Intangible assets, Accumulated Amortization	(1,642)	(1,476)
Intangible assets, Net Carrying Value	$ 1,475	$ 1,641

Intangibles - Estimated Future

Intangibles - Estimated Future Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2022	$ 56
2023	223
2024	223
Thereafter	973
Intangible assets, Net Carrying Value	$ 1,475	$ 1,641

License Agreements - Additional

License Agreements - Additional Information (Detail) - University of Bristol [Member] - USD ($)		9 Months Ended
	Jan. 22, 2018	Sep. 30, 2022	Jul. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum amount payable under license agreement, tied to milestones			$ 3,200,000
Payments under license agreement		$ 125,000
Amendment to the University of Bristol License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum amount payable under license agreement, tied to milestones	$ 1,700,000
Payments under license agreement	$ 37,500

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2022
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Maximum maturity period of cash and cash equivalents	90 days
Maximum [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Maturity period of securities	1 year

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] $ in Thousands	Sep. 30, 2022 USD ($)
Assets
Total assets	$ 15,506
Money market securities (cash equivalents) [Member]
Assets
Total assets	15,456
Restricted cash [Member]
Assets
Total assets	50
Level 1 [Member]
Assets
Total assets	15,506
Level 1 [Member] | Money market securities (cash equivalents) [Member]
Assets
Total assets	15,456
Level 1 [Member] | Restricted cash [Member]
Assets
Total assets	$ 50

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Cash Equivalents (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash equivalents, amortized cost and estimated fair value	$ 15,456
Restricted cash, amortized cost and estimated fair value	50
Money market securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash equivalents, amortized cost and estimated fair value	15,456
Restricted cash, amortized cost and estimated fair value	$ 50

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Convertible Debt, Principal Amount	$ 15,000	$ 15,000
Convertible Debt, Carrying Value	15,763	14,920
Convertible Debt, Fair Value	$ 16,548	$ 15,204

Convertible Debt - Additional I

Convertible Debt - Additional Information (Details) $ / shares in Units, $ in Thousands	Apr. 26, 2022 USD ($)	Dec. 22, 2021 USD ($) Day $ / shares	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Convertible Debt [Line Items]
Convertible debt principal amount			$ 15,000	$ 15,000
Convertible debt, interest rate		2.25%
Convertible debt compound interest		7%
Prime Rate Minus 1.0% [Member]
Convertible Debt [Line Items]
Convertible debt, interest rate		1%
SVB [Member]
Convertible Debt [Line Items]
Maturity date	Apr. 01, 2026
Convertible debt, interest rate	3.50%
Debt instrument, repayment terms	Commencing on May 1, 2024, the outstanding loans under the Loan Agreement will be repaid in 24 consecutive equal monthly installments of principal plus accrued and unpaid interest.
Aggregate principal amount of term loan advances extended percentage	6%
Debt instrument, liquidity ratio	1.25
Minimum market capitalization	$ 250,000
Drawn amount			$ 0
SVB [Member] | Minimum [Member]
Convertible Debt [Line Items]
Net cash proceeds from the issuance and sale of equity securities	30,000
SVB [Member] | Contingent Convertible Debt Agreement [Member]
Convertible Debt [Line Items]
Convertible debt principal amount		$ 25,000
Maturity date		Dec. 22, 2023
Extendable maturity date		Dec. 22, 2024
Conversion price per share | $ / shares		$ 9.34
Stock price trigger | $ / shares		$ 24
Threshold consecutive trading days | Day		30
SVB [Member] | Contingent Convertible Debt Agreement [Member] | Before 18-Month Anniversary [Member]
Convertible Debt [Line Items]
Percentage of principal amount to be repaid		125%
SVB [Member] | Contingent Convertible Debt Agreement [Member] | After 18-Month Anniversary [Member]
Convertible Debt [Line Items]
Percentage of principal amount to be repaid		150%
SVB [Member] | Contingent Convertible Debt Agreement [Member] | Convertible Indebtedness [Member]
Convertible Debt [Line Items]
Convertible debt principal amount		$ 15,000
SVB [Member] | Contingent Convertible Debt Agreement [Member] | Non-Convertible Term Loans [Member]
Convertible Debt [Line Items]
Convertible debt principal amount	$ 10,000

Convertible Debt - Schedule of

Convertible Debt - Schedule of Convertible Debt Balance (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Convertible Debt Information
Convertible Debt, Principal Amount	$ 15,000	$ 15,000
Transaction Costs	(84)	(109)
Accrued paid-in-kind interest	847	29
Convertible debt	$ 15,763	$ 14,920

Common Stock - Authorized - Add

Common Stock - Authorized - Additional Information (Detail) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Common stock, shares authorized	150,000,000	150,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000
Preferred stock, par value	$ 0.001

Common Stock - Issued and Outst

Common Stock - Issued and Outstanding Shares - Additional Information (Detail) - USD ($)		3 Months Ended						9 Months Ended
	May 27, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option exercises, Shares		0			0			0		0
Restricted stock unit settlements		26,625			231			26,625		231
May 2021 Public Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Gross proceeds from issuance of common stock	$ 23,000,000
Underwriting discounts and commissions and offering expenses	1,700,000
Proceeds from issuance of common stock	$ 21,300,000
At-the-Market Sales Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued								200,000	200,000
Common stock aggregate maximum offering amount		$ 25,000,000						$ 25,000,000	$ 25,000,000
Gross proceeds								1,500,000	1,500,000
Common stock available for sale under offering		$ 23,500,000						$ 23,500,000	$ 23,500,000
Common stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued				3,584		2,149	2,965
Restricted stock unit settlements			26,625		145
Common stock [Member] | May 2021 Public Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued	3,285,714
Common stock, price per share	$ 7
Common stock [Member] | Underwriters Over-Allotment Option Exercise [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued	428,571

Common Stock - Stock Options -

Common Stock - Stock Options - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for options currently outstanding	822,515		522,090
Number of shares granted	300,450
Unrecognized compensation expense related to stock options granted	$ 3.7
Anti-dilutive securities excluded from earning per share computation	2,315,337	1,818,996
Warrant [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Anti-dilutive securities excluded from earning per share computation	1,239,947
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Anti-dilutive securities excluded from earning per share computation	822,515
Restricted Stock Unit [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Anti-dilutive securities excluded from earning per share computation	252,875
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average period, restricted stock awards	2 years 2 months 1 day
Stock Options [Member] | Employees and Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
Stock Options [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award expiration period	7 years
Stock Options [Member] | Minimum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	1 year
Stock Options [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award expiration period	10 years
Stock Options [Member] | Maximum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
Restricted Stock Unit [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares reserved for issuance under incentive plan	252,875
Award vesting period	4 years
Common shares reserved for awards currently outstanding	252,875		53,250
Weighted-average period, restricted stock awards	10 months 17 days
2018 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for issuance under incentive plan	122
Award expiration period	10 years
2018 Equity Incentive Plan [Member] | Minimum [Member] | Employees and Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
2018 Equity Incentive Plan [Member] | Minimum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	1 year
2018 Equity Incentive Plan [Member] | Maximum [Member] | Employees and Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
2018 Equity Incentive Plan [Member] | Maximum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
2018 Equity Incentive Plan [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for issuance under incentive plan	967,152
Common shares reserved for options currently outstanding	714,155
New Employee Inducement Grants [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for options currently outstanding	95,000
Award expiration period	10 years
Number of shares granted	50,000
2017 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award expiration period	10 years
2017 Equity Incentive Plan [Member] | Minimum [Member] | Employees and Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
2017 Equity Incentive Plan [Member] | Minimum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	1 year
2017 Equity Incentive Plan [Member] | Maximum [Member] | Employees and Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
2017 Equity Incentive Plan [Member] | Maximum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
2017 Equity Incentive Plan [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for issuance under incentive plan	13,156
2010 Performance Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award expiration period	10 years
2010 Performance Incentive Plan [Member] | Minimum [Member] | Employees and Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
2010 Performance Incentive Plan [Member] | Minimum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	1 year
2010 Performance Incentive Plan [Member] | Maximum [Member] | Employees and Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
2010 Performance Incentive Plan [Member] | Maximum [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
2010 Performance Incentive Plan [Member] | Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for issuance under incentive plan	204
Common shares reserved for options currently outstanding	204
2010 Performance Incentive Plan [Member] | Restricted Stock Unit [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for awards currently outstanding	0

Common Stock - Summary of Stock

Common Stock - Summary of Stock Options Activity (Detail)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 26.11
Weighted Average Exercise Price, Granted | $ / shares	7.83
Weighted Average Exercise Price, Expired | $ / shares	28,522.56
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 18.57
Number of Optioned Common Shares, Beginning Balance | shares	522,090
Number of shares granted | shares	300,450
Number of Optioned Common Shares, Expired | shares	(25)
Number of Optioned Common Shares, Ending Balance | shares	822,515

Common Stock - Summary of Fair

Common Stock - Summary of Fair Value of Each Stock Award for Employees and Directors (Detail)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	1.65%	0.64%
Expected dividend yield	0%	0%
Expected life	5 years 9 months 18 days	5 years 11 months 26 days
Expected volatility	122.80%	109.61%

Common Stock - Summary of Share

Common Stock - Summary of Share-Based Compensation Expense for Stock Options, Restricted Stock and Employee Share Purchase Plan (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 829	$ 530	$ 2,492	$ 1,693
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	288	162	852	526
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 541	$ 368	$ 1,640	$ 1,167

Common Stock - Restricted Stock

Common Stock - Restricted Stock Unit Awards - Additional Information (Detail) - Restricted Stock Unit [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period			4 years
Stock based compensation expense	$ 0.3	$ 0.1	$ 0.8	$ 0.3
Total unrecognized compensation expense related to the Company's restricted stock unit awards	$ 1.5		$ 1.5
Weighted-average period, restricted stock awards			10 months 17 days

Common Stock - Summary of Restr

Common Stock - Summary of Restricted Stock Unit Award Activity (Detail) - Restricted Stock Unit [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	53,250
Number of Shares, Granted | shares	226,250
Number of Shares, Released | shares	(26,625)
Number of Shares, Ending Balance | shares	252,875
Weighted-Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 13.09
Weighted-Average Grant Date Fair Value, Granted | $ / shares	8.26
Weighted-Average Grant Date Fair Value, Released | $ / shares	13.09
Weighted-Average Grant Date Fair Value, Released | $ / shares	$ 8.77

Common Stock - Employee Share P

Common Stock - Employee Share Purchase Plan - Additional Information (Detail) - Employee Share Purchase Plan	9 Months Ended
	Sep. 30, 2022 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares authorized to purchased	200,000
Number of shares purchased	28,892

Common Stock - Summary of Outst

Common Stock - Summary of Outstanding Warrants (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Warrants Issued in September 2017 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	411
Exercise price per Share	$ 699.200
Expiration Date	2023-03
Warrants Issued in June 2018 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	114,100
Exercise price per Share	$ 80
Expiration Date	2023-06
Warrants Issued in October 2018 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	31,215
Exercise price per Share	$ 62.890
Expiration Date	2023-10
Warrants Issued in May 2019 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	60,000
Exercise price per Share	$ 90
Expiration Date	2025-05
Warrants Issued in December 2019 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	609,258
Exercise price per Share	$ 6.600	$ 6.60
Expiration Date	2024-12
Warrants Issued in April 2020 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	182,461
Exercise price per Share	$ 7.240
Expiration Date	2025-04
Warrants Issued in April 2020 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	24,375
Exercise price per Share	$ 7.320
Expiration Date	2025-04
Warrants Issued in April 2020 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	25,270
Exercise price per Share	$ 7.590
Expiration Date	2025-04
Pre-Funded Warrants Issued in August 2020 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	142,857
Exercise price per Share	$ 0.001
Warrants Issued in December 2020 [Member]
Class of Warrant or Right [Line Items]
Total Outstanding and Exercisable	50,000
Exercise price per Share	$ 8.750
Expiration Date	2025-12

Common Stock - Common Stock War

Common Stock - Common Stock Warrants - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Class of Warrant or Right [Line Items]
Proceeds from exercise of warrants	$ 24,000	$ 339,000
Warrants Issued in December 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock	3,709	47,084
Exercise price per share of warrant	$ 6.600	$ 6.60
Proceeds from exercise of warrants	$ 24,480	$ 300,000
Warrants Issued in April 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock	3,750
Exercise price per share of warrant	$ 7.32
Proceeds from exercise of warrants	$ 27,450

Commitments and Contingencies -

Commitments and Contingencies - Summary of Contractual Obligations (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
Total	$ 21
Less than 1 year	21
Vancouver Office Operating Lease [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
Total	21
Less than 1 year	$ 21

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail)			3 Months Ended		9 Months Ended
	Nov. 19, 2018 USD ($) ft²	Dec. 11, 2017 ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Mar. 01, 2018 USD ($)
Other Commitments [Line Items]
Consolidated rent expense			$ 25,000	$ 29,000	$ 91,000	$ 100,000
Indemnification obligations			$ 0		0
Expenses related to indemnification issues					$ 0
Vancouver Lease Arrangement [Member] | Vancouver, British Columbia [Member]
Other Commitments [Line Items]
Lease agreement commencement date	Feb. 01, 2019
Area of office space leased | ft²	2,367
Initial term of lease expiration date	Jan. 31, 2023
Operating lease, term of contract	4 years
Operating lease, option to extend, description					The initial term of the Vancouver Lease will expire on January 31, 2023, with an option to extend the term for one further four-year period
Lessee, Operating Lease, Existence of Option to Extend [true false]					true
Operating lease, initial monthly base rent expenses	$ 5,200
Operating lease, revised monthly base rent expenses	5,400
Construction allowance	14,200
Security deposit	$ 18,600
Seattle Lease Arrangement [Member] | Pike [Member]
Other Commitments [Line Items]
Area of office space leased | ft²		3,187
Initial term of lease expiration date		Mar. 01, 2021
Lease agreement					On December 11, 2017, we entered into a lease, or the Seattle Lease, with 520 Pike Street, Inc., or Pike, pursuant to which we leased approximately 3,187 square feet located at Suite 2250 at 520 Pike Tower, Seattle, Washington, 98101, which commenced on March 1, 2018. The Seattle Lease expired on March 1, 2021 and was not renewed.
Monthly base rent							$ 11,685
Monthly base rent, maximum annual increase							12,397
Lease, security deposit, annual payment							37,192
Lease, security deposit payment first anniversary							12,397
Lease, security deposit payment two anniversary							12,397
Lease, security deposit payment remaining amount							$ 12,397

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments (Detail) - Vancouver Office Operating Lease [Member] $ in Thousands	Sep. 30, 2022 USD ($)
Operating Leased Assets [Line Items]
2022	$ 16
2023	5
Total	$ 21

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Other Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows to operating leases	$ 16	$ 15	$ 45	$ 68
Right-of-use assets obtained in exchange for lease obligations:
Weighted Average Remaining Lease Term Operating leases	3 months 29 days	1 year 3 months 29 days	3 months 29 days	1 year 3 months 29 days
Weighted Average Discount Rate Operating leases	9.97%	9.97%	9.97%	9.97%